Transient Ischemic Attack News and Research

RSS
A transient ischemic attack (TIA) is a transient stroke that lasts only a few minutes. It occurs when the blood supply to part of the brain is briefly interrupted. TIA symptoms, which usually occur suddenly, are similar to those of stroke but do not last as long. Most symptoms of a TIA disappear within an hour, although they may persist for up to 24 hours. Symptoms can include: numbness or weakness in the face, arm, or leg, especially on one side of the body; confusion or difficulty in talking or understanding speech; trouble seeing in one or both eyes; and difficulty with walking, dizziness, or loss of balance and coordination.
Two stroke-prevention procedures are equally beneficial for men and women, but effectiveness vary by age

Two stroke-prevention procedures are equally beneficial for men and women, but effectiveness vary by age

Minimally-invasive procedure as effective as gold standard for treating carotid artery blockages: Study

Minimally-invasive procedure as effective as gold standard for treating carotid artery blockages: Study

Overall incidence of stroke, heart attack and death similar in carotid endarterectomy and stenting procedures

Overall incidence of stroke, heart attack and death similar in carotid endarterectomy and stenting procedures

CREST stroke prevention trial: Seminal and robust

CREST stroke prevention trial: Seminal and robust

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Nearly 40% of TIA and minor ischemic stroke patients may experience mental impairment

Acute stroke care and clinical outcomes improve substantially with stroke program

Acute stroke care and clinical outcomes improve substantially with stroke program

NMT Medical completes private placement of common stock and warrants for $5.8M

NMT Medical completes private placement of common stock and warrants for $5.8M

NMT Medical announces preliminary unaudited figures for fiscal 2009

NMT Medical announces preliminary unaudited figures for fiscal 2009

Memory loss or decline in thinking abilities may indicate higher risk of stroke

Memory loss or decline in thinking abilities may indicate higher risk of stroke

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

Treatment with Effient more cost effective, show TRITON-TIMI 38 clinical trial results

RRE-90 score: A new web-based tool to predict recurrent stroke risk

RRE-90 score: A new web-based tool to predict recurrent stroke risk

ZYPREXA RELPREVV approved by FDA

ZYPREXA RELPREVV approved by FDA

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

MICARDIS receives Health Canada approval to reduce the risk of non-fatal stroke

Updated clinical guidelines on Effient treatment for ACS patients

Updated clinical guidelines on Effient treatment for ACS patients

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

Incidence of stroke related to coronary angioplasty remain steady over a 15-year period: Mayo Clinic study

Interim data from Schering-Plough's narlaprevir Phase IIa study

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough receives FDA complete response letter regarding PEGINTRON

NMT Medical reports financial results for third-quarter 2009; narrows net loss to $0.22 per share

NMT Medical reports financial results for third-quarter 2009; narrows net loss to $0.22 per share